FDA approves Novartis Rhapsido as first treatment for symptomatic dermographism

Adults who live with symptomatic dermographism, a chronic skin condition in which light pressure, rubbing or scratching produces raised, red and intensely itchy hives within minutes, have long been offered little beyond a daily antihistamine. For more than half of them, that approach fails. On October 7, 2026, the U.S. Food and Drug Administration approved Rhapsido (remibrutinib) as the first treatment indicated specifically for adults with symptomatic dermographism whose symptoms are inadequately controlled by H1 antihistamines.

Remibrutinib is an oral, highly selective Bruton's tyrosine kinase inhibitor developed by Novartis. It blocks the BTK pathway involved in the release of histamine, a key driver of hives and swelling. With the new label, it becomes the only prescription treatment with approved uses in both of the two most common forms of chronic hives. Novartis says more than 90 percent of adults with chronic hives experience either chronic spontaneous urticaria or symptomatic dermographism, and Rhapsido now covers both.

The approval expands a franchise that began on September 30, 2025, when the FDA first cleared remibrutinib for chronic spontaneous urticaria on the strength of the phase 3 REMIX-1 and REMIX-2 trials. The medicine is also approved for that condition in the European Union, the United Kingdom and China. The new indication keeps the same 25 mg twice-daily oral dose, and Novartis said the safety profile in symptomatic dermographism was consistent with the earlier hives program.

Symptomatic dermographism is the most prevalent type of chronic inducible urticaria, a family of conditions in which a physical trigger such as pressure, cold, heat or exercise sets off the wheals. Novartis notes that more than 50 percent of patients remain symptomatic despite taking H1 antihistamines. The condition is chronic rather than episodic: in the pivotal study, participants had lived with it for a mean of 5.8 years.

Key Facts

The FDA decision rests on the phase 3 RemIND trial, a 52-week, multicenter, randomized, double-blind, placebo-controlled study registered as NCT05976243. It enrolled 115 adults who had had symptomatic dermographism for at least four months despite background H1 antihistamines. To qualify, patients needed a Total Fric Score of 3 or higher on the 0 to 4 FricTest 4.0 scale and an itch numeric rating scale score of 5 or higher after provocation. Participants were randomized one to one to remibrutinib 25 mg or placebo twice daily for 24 weeks, followed by a 28-week open-label period in which everyone received the active drug.

At Week 12, 29.3 percent of patients taking remibrutinib achieved a complete response, meaning their Total Fric Score fell to zero, compared with 14.0 percent on placebo, a treatment difference of 15.0 percentage points (95 percent confidence interval 0.3 to 29.7; p=0.0229). In raw numbers, 17 of 58 patients on the drug cleared their hives completely versus 8 of 57 on placebo. HCPLive reported on October 7, 2026 that the trial also captured an early signal: at Week 2, 29.3 percent of treated patients had a complete response versus 8.8 percent on placebo, a gap of 20.5 percentage points. By Week 24, complete response was 32.8 percent on remibrutinib versus 15.8 percent on placebo.

Itch fell quickly too. Remibrutinib reduced the itch numeric rating scale by a least-squares mean of 4.0 points from baseline at Week 2, against 1.8 points for placebo. The population skewed young and female: mean age was 39.2 years, 71.3 percent (82 of 115) were women, and 58.3 percent (67 of 115) entered the trial with the maximum baseline Total Fric Score of 4. HCPLive reported on October 7, 2026 that the label advises interrupting remibrutinib for 3 to 7 days before and after surgery and avoiding live vaccines and strong or moderate CYP3A4 inhibitors or inducers.

Safety through Week 24 was consistent with the chronic spontaneous urticaria program. In pooled CSU trials, the most common adverse reactions were nasopharyngitis at 11 percent, bleeding at 9 percent, headache at 7 percent, nausea at 3 percent and abdominal pain at 3 percent, with no severe bleeding events. Novartis said the most common adverse events in symptomatic dermographism, at an incidence of 3 percent or greater, were nasopharyngitis, bleeding, headache, nausea and abdominal pain, and that no routine laboratory monitoring is required.

Reuters reported on October 7, 2026 that the FDA expanded the use of Novartis's remibrutinib for adults with the chronic itchy-welt condition, adding momentum for a drug investors have watched closely after late-stage failures of the company's cholesterol drug pelacarsen and its muscle-wasting disease therapy del-desiran increased scrutiny of the pipeline. AJMC reported on October 7, 2026 that remibrutinib is now the only prescription treatment approved for both chronic spontaneous urticaria and symptomatic dermographism.

Analysis

The headline number, 29.3 percent versus 14.0 percent, deserves a careful reading. What this really means is that roughly seven in ten patients on the drug still did not achieve complete clearance of their hives at Week 12 by the trial's strictest measure. Placebo response in this disease is real and measurable, and a 15 percentage point separation, with a confidence interval that begins just above zero, is a genuine but not overwhelming effect. The Week 2 data, where the gap was 20.5 percentage points, suggest the drug works quickly in the patients it helps, but the ceiling on complete response remains the central clinical fact.

The bigger picture here is about what kind of drug this is. Remibrutinib is not a rescue therapy or an injected biologic; it is a twice-daily oral pill requiring no routine lab monitoring, which matters enormously for a condition patients manage at home every day. The strategic logic for Novartis is equally plain: the company now holds the only label covering both chronic spontaneous urticaria and symptomatic dermographism, the two diagnoses behind more than 90 percent of adult chronic hives. That moat is built less on one spectacular trial result than on breadth of indication.

Investors will weigh the broader context. Reuters reported on October 7, 2026 that remibrutinib has become a focus for shareholders after setbacks elsewhere in the pipeline, and noted that the approval follows positive late-stage results for the drug in relapsing multiple sclerosis, a disease in which the immune system attacks the nervous system. Novartis has separately reported positive topline phase 3 REMODEL-1 and REMODEL-2 results in relapsing multiple sclerosis versus teriflunomide, and continues to study remibrutinib in hidradenitis suppurativa and food allergy.

Clinicians gain something they have not had before: a labeled option for a patient group long told there was nothing more to offer once antihistamines failed. Giselle Mosnaim, MD, MS, an allergist and immunologist at Endeavor Health and a clinical professor at the University of Chicago Pritzker School of Medicine who led the RemIND trial, described the condition as chronic and debilitating with historically limited treatment options. Kristen Willard, executive director of the patient community We CU, called the approval important progress for the SD community.

Why It Matters

For patients, the practical meaning is a shift from off-label improvisation to an evidence-based pathway. Symptomatic dermographism is not a cosmetic nuisance: it produces hives within minutes of ordinary contact, persists for years, and drives itch that interferes with sleep, work and clothing choices. A therapy that cut itch by 4.0 points on a numeric rating scale at Week 2, against 1.8 for placebo, is a measurable change for the quarter of patients who respond completely and a partial benefit for others.

For the field of chronic urticaria, the approval validates BTK inhibition as a mechanism reaching beyond spontaneous hives into the inducible forms. RemIND did not stop at symptomatic dermographism: it also evaluated cold urticaria and cholinergic urticaria. If those cohorts yield supportive data, the same oral pill could cover a larger share of the physical-urticaria spectrum, a prospect no injected biologic has yet matched.

For Novartis, the calculus is pipeline insurance. With shareholders focused on late-stage disappointments, a second approved indication on an already-manufactured oral drug, at the same 25 mg twice-daily dose, is a low-cost way to add revenue and credibility while strengthening the company's immunology position ahead of a possible multiple sclerosis filing.

Next Up

Novartis said it plans to submit the full RemIND dataset to health authorities globally, which opens the question of how quickly the symptomatic dermographism indication reaches the European Union, the United Kingdom and China, where the drug is currently approved only for chronic spontaneous urticaria. Regulators in those markets will review the same 115-patient dataset, the Week 12 complete response rates of 29.3 percent versus 14.0 percent, and the Week 24 figures of 32.8 percent versus 15.8 percent.

Beyond that, attention turns to the rest of the remibrutinib program, including hidradenitis suppurativa, food allergy and relapsing multiple sclerosis, where the company has reported positive topline phase 3 results from REMODEL-1 and REMODEL-2. If those readouts convert into approvals, the BTK inhibitor that began as a chronic hives drug could end up with a portfolio of labels few immunology assets can match.